Related references
Note: Only part of the references are listed.Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
Lucilla Parnetti et al.
MOVEMENT DISORDERS (2014)
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Lucilla Parnetti et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
The Genetics of Parkinson's Disease: Progress and Therapeutic Implications
Andrew B. Singleton et al.
MOVEMENT DISORDERS (2013)
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway
Youren Tong et al.
MOLECULAR NEURODEGENERATION (2012)
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function
Min Shi et al.
NEUROBIOLOGY OF AGING (2012)
Regulation of Physiologic Actions of LRRK2: Focus on Autophagy
Andrew Ferree et al.
NEURODEGENERATIVE DISEASES (2012)
Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
Min Shi et al.
ANNALS OF NEUROLOGY (2011)
CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease
Michael R. Sierks et al.
INTEGRATIVE BIOLOGY (2011)
Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naive Patients with Parkinson's Disease
Min Jeong Park et al.
JOURNAL OF CLINICAL NEUROLOGY (2011)
Olfactory Deficits and Cardiac 123I-MIBG in Parkinson's Disease Related to the LRRK2 R1441G and G2019S Mutations
Javier Ruiz-Martinez et al.
MOVEMENT DISORDERS (2011)
Olfactory dysfunction in LRRK2 G2019S mutation carriers
R. Saunders-Pullman et al.
NEUROLOGY (2011)
Subclinical signs in LRRK2 mutation carriers
Krisztina K. Johansen et al.
PARKINSONISM & RELATED DISORDERS (2011)
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
Novel Pathogenic LRRK2 p.Asn1437His Substitution in Familial Parkinson's Disease
Jan O. Aasly et al.
MOVEMENT DISORDERS (2010)
Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers
Vesna Sossi et al.
MOVEMENT DISORDERS (2010)
Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation
Christian Wider et al.
NEURODEGENERATIVE DISEASES (2010)
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda et al.
NEUROLOGY (2010)
Genealogical studies in LRRK2-associated Parkinson's disease in central Norway
Krisztina K. Johansen et al.
PARKINSONISM & RELATED DISORDERS (2010)
Detection of elevated levels of soluble -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies
Katerina E. Paleologou et al.
BRAIN (2009)
Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein
Xian Lin et al.
NEURON (2009)
Protein aggregation in the brain: The molecular basis for Alzheimer's and Parkinson's diseases
G. Brent Irvine et al.
MOLECULAR MEDICINE (2008)
Progression of dopaminergic dysfunction in a LRRK2 kindred A multitracer PET study
R. Nandhagopal et al.
NEUROLOGY (2008)
Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease
Omar M. A. El-Agnaf et al.
FASEB JOURNAL (2006)
Clinical features of LRRK2-associated Parkinson's disease in Central Norway
JO Aasly et al.
ANNALS OF NEUROLOGY (2005)
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease
WC Nichols et al.
LANCET (2005)
Common LRRK2 mutation in idiopathic Parkinson's disease
WP Gilks et al.
LANCET (2005)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
α-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma
OMA El-Agnaf et al.
FASEB JOURNAL (2003)
Share Paper
